[Chinese expert consensus on the diagnosis, treatment and comprehensive management of very old or frail patients with diffuse large B-cell lymphoma (2025)].

As the aging population increases, the proportion of elderly patients with diffuse large B-cell lymphoma (DLBCL) is significantly rising. Comprehensive geriatric assessment plays a crucial role in assessing chemotherapy tolerance. Very old or frail DLBCL patients classified by comprehensive geriatric assessment exhibit reduced tolerance to chemotherapy and multiple comorbidities, necessitating tailored treatment plans. To enhance the diagnostic and therapeutic capabilities of clinicians in China regarding very old or frail DLBCL patients classified by comprehensive geriatric assessment, the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and the Lymphatic Disease Society of the Chinese Medical Education Association have convened relevant experts to formulate this consensus.